HRMY Lifts Revenue Guidance After Record Q3 WAKIX Growth and Highest-Ever Patient Gains
Strong Q3 WAKIX Results Lead to Revenue Target Hike
Harmony Biosciences (NASDAQ: HRMY) delivered a significant update this morning, announcing preliminary third-quarter results for 2025 that underscore both accelerating demand and commercial momentum for its flagship narcolepsy treatment, WAKIX (pitolisant). According to the company, net revenue for the WAKIX franchise hit an estimated $239 million in Q3 2025, marking 29% growth over the prior year.
This sales jump was powered by the highest ever quarterly patient increase—up by about 500—to an average of 8,100 patients. The robust numbers prompted Harmony to raise its full-year 2025 revenue guidance, now targeting a range of $845 to $865 million (previously $820 to $860 million). This adjustment highlights the company’s confidence in its path toward achieving blockbuster drug status in the narcolepsy market.
| Key Metric | Q3 2025 Result | Year-Over-Year Change |
|---|---|---|
| WAKIX Net Revenue | $239M | +29% |
| Average Patients | 8,100 | +500 patients (highest quarterly gain) |
| 2025 Revenue Guidance | $845–$865M | Up from $820–$860M |
Market Adoption Accelerates as Blockbuster Status Looms
What’s particularly striking about this quarter is the acceleration in patient adoption. WAKIX not only sustained double-digit sales growth, but did so while achieving its largest jump in new patients to date. CEO Jeffrey Dayno noted that this trend "positions Harmony well for future growth," reflecting increased confidence both internally and potentially from investors.
These preliminary results signal more than just a sales boost; they point to deepening market penetration and validate WAKIX’s status as the only FDA-approved medication of its kind for excessive daytime sleepiness or cataplexy in narcolepsy. With more than 170,000 Americans living with narcolepsy—and current treatment options often limited—the rapid uptake of WAKIX highlights ongoing unmet need and suggests Harmony could be on track to make its therapy a blockbuster, defined as over $1 billion in annual revenue.
Full Earnings, Forward Guidance, and Risks
Harmony plans to share complete Q3 2025 results and hold an investor conference call on November 4th. Investors and market watchers will look for details on sustainability of this momentum, patient growth rates, and management commentary on competitive dynamics or broader plans, such as new indications or expanded market reach for WAKIX.
It's important to note that these figures are preliminary and unaudited, and final numbers could shift as quarterly closing processes conclude. Additionally, investors should be mindful of warnings around possible safety considerations and known risks associated with WAKIX use, including potential interactions, the need for dosage adjustments in certain populations, and typical adverse effects observed in clinical trials. A more granular breakdown is expected with the formal quarterly report.
Key Takeaway: All Eyes on WAKIX's Trajectory Ahead of Full Earnings
This morning’s preannouncement puts Harmony Biosciences in a bright spot as it accelerates revenue growth, achieves new milestones in patient adoption, and lifts expectations for 2025. For investors, healthcare analysts, and anyone watching the rare disease therapeutic landscape, the central question remains: can WAKIX’s growth trajectory keep up its current pace and deliver the blockbuster milestone? With a full earnings call set for November 4th, that answer may be just around the corner.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI